On October 21, 2021 Artiva Biotherapeutics, Inc., ("Artiva") an oncology company focused on developing and commercializing off-the-shelf, allogeneic natural killer (NK) cell-based therapies to treat cancer, reported an upcoming presentation describing AB-201, an anti-HER2 CAR-NK cell therapy candidate, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 36th Annual Meeting and Pre-Conference Programs to be held November 10-14, 2021, virtually and in-person at the Walter E. Washington Convention Center in Washington, D.C (Press release, Artiva Biotherapeutics, OCT 21, 2021, View Source [SID1234591680]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The full abstract is scheduled to be available on the SITC (Free SITC Whitepaper) website on November 9, 2021.

Poster Presentation Info:

Title: Development of AB-201, a novel allogeneic anti-HER2-specific CAR-NK cell therapy for the treatment of HER2+ tumors
Abstract Number: #129
Date: November 12 – 13, 2021
Time: 7:00 am – 8:30 pm ET
Location: Hall E
About HER2+ Solid Tumors

HER2 is a receptor tyrosine kinase that is overexpressed on many solid tumors, including breast, gastric, and bladder cancers. It is estimated that there are over 50,000 patients diagnosed annually in U.S. with tumors having high HER2 expression, with overexpression found in approximately 20% of breast cancer cases and in over 10% of bladder and gastric cancers. Currently, there are eight approved HER2-directed therapies including monoclonal antibodies, antibody-drug conjugates, and small molecule kinase inhibitors. While many patients with advanced HER2+ cancers derive meaningful benefit from HER2-targeted therapies, they typically progress beyond approved therapies, and treatment of these patients remains a large unmet medical need.

About AB-201

AB-201 is an allogeneic anti-HER2 CAR-NK cell therapy candidate manufactured from cord blood, containing a proprietary HER2 antigen recognition domain. Artiva is developing AB-201 for the treatment of HER2-overexpressing tumors, such as breast, gastric, and bladder cancers. The company is currently manufacturing AB-201 in large scale bioreactors, resulting in potentially thousands of doses of product from a single donor cord blood unit.

On October 21, 2021 Amgen (NASDAQ:AMGN) reported that its Board of Directors declared a $1.76 per share dividend for the fourth quarter of 2021 (Press release, Amgen, OCT 21, 2021, View Source [SID1234591679]). The dividend will be paid on December 8, 2021, to all stockholders of record as of the close of business on November 16, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 21, 2021 Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, reported that it will report financial results and provide a business update for the third quarter ended September 30, 2021, before the US markets open on Thursday, November 4, 2021 (Press release, Adaptimmune, OCT 21, 2021, View Source [SID1234591678]). Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (12:00 p.m. GMT) that same day (details below).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The press release will be available in the investor section of Adaptimmune’s corporate website at www.adaptimmune.com. A live webcast of the conference call and replay can be accessed at https://bit.ly/3utRMny.

To participate in the live conference call, please dial (833) 652-5917 (U.S. or Canada) or +1 (430) 775-1624 (International). After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (4557667).

On October 21, 2021 Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, reported that Vish Seshadri, Ph.D., M.B.A., Chief Executive Officer of Abeona, is scheduled to present at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021, at 3:30 p.m. ET (Press release, Abeona Therapeutics, OCT 21, 2021, View Source [SID1234591677]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live and archived webcast of the presentation will be available on the investor section of the Abeona Therapeutics website at www.abeonatherapeutics.com.

On October 21, 2021 Leucid Bio ("Leucid" or the "Company"), a biotech company pioneering next-generation cell therapies for hard-to-treat cancers, reported that it has successfully raised £11.5 million in a Series A financing round (Press release, Leucid Bio, OCT 21, 2021, View Source [SID1234591675]). The investment was led by Epidarex and new investor Vulpes Investment Management, with participation from new investors 2Invest and Future Fund of the British Business Bank, and existing investor Sofinnova Partners. Proceeds from the financing will be used to initiate a Phase 1 trial of its lead candidate, LEU-011, for the treatment of platinum resistant ovarian cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CAR T-cell therapy is a revolutionary technology in which the patient’s own immune cells are reprogrammed so they can recognise and destroy cancer cells. This has proven to be a powerful therapy for refractory blood cancers but has not yet been very effective for the treatment of solid cancers.

Leucid was founded to translate 20 years of pioneering CAR-T research led by Dr John Maher at King’s College London who joined the Company from inception as its Chief Scientific Officer. Leucid has developed a proprietary engine that builds upon Dr Maher’s novel CAR-T model which develops CAR-T molecules designed to be in a more natural biological configuration of cells. The early development work was supported by the National Institute for Health Research (NIHR) Guy’s and St Thomas’ Biomedical Research Centre. The Company’s technology gives properties to the CAR-Ts that enable them to consistently outperform previous generations of CAR-T therapies in pre-clinical studies; enhancing T-cell potency and generating a persistent long-term response with reduced toxicity.

Leucid’s LEU-011 programme is a NKG2D CAR T-cell therapy in pre-clinical development for the treatment of solid tumours and haematological malignancies. The NKG2D receptor is an activating immune receptor that triggers cell death upon recognition of human NKG2D ligands expressed on transformed, infected or damaged cells. LEU-011 has potential for the treatment of multiple cancer types as NKG2D ligands are expressed on more than 80% of human tumour cells.

In conjunction with the Series A financing, Ian Miscampbell, Managing Partner of Sixth Element Capital LLP, has been appointed Chair of the Board, while Martin Diggle, Portfolio Manager of Vulpes Life Science Fund will join the Board of Directors as Non-Executive Director, and Heikki Lanckriet as Board Observer for 2Invest. Epidarex’s Peter Finan currently sits on the Board as Investment Director, and Graziano Seghezzi, Managing Partner of Sofinnova, and Michael Garrison, Director at King’s College London remain as Observers to the Board.

Artin Moussavi, Chief Executive Officer of Leucid Bio, said: "We are excited to welcome new investors to Leucid Bio. With support from this high calibre syndicate, the financing will enable us to progress our lead programme, LEU-011, into clinical development. At Leucid we are developing improved CAR-T technologies aimed to overcome key challenges in CAR T-cell therapy for solid tumours, to improve treatment outcomes and save the lives of cancer patients, where current treatments are not currently proving to be as clinically meaningful as required."

Ian Miscampbell, Chair of Leucid Bio’s Board of Directors, commented: "I am delighted to be joining as Chair of this trail-blazing Company as it moves into the clinical development phase, developing novel CAR-T therapies for patients who do not currently have a treatment option. I have been impressed by the excellent work achieved by the Leucid team and am excited to establish Leucid as a leading next generation CAR-T company."

Peter Finan, Partner at Epidarex Capital, said: "The new financing will allow us to explore Leucid’s ground-breaking technology in a clinical setting. We remain optimistic that with the right therapeutic approach, the challenges for CAR-T therapy in a solid tumour setting can be overcome. We look forward to working closely with the Leucid team and our co-investors to realise the potential of Leucid’s technology."

Martin Diggle, Principal at Vulpes Life Sciences, stated: "After performing extensive scientific due diligence, Vulpes is delighted to cornerstone this important fundraise to enable Leucid to advance its exciting cancer therapies. We believe Professor John Maher’s team has one of the most promising approaches to treating solid tumours in the world today and we are excited by the possibilities of its CAR-T research to date."